Categories: News

Streamline Health® To Report Third Quarter 2021 Financial Performance and Provide Corporate Update

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ATLANTA, GA, Dec. 02, 2021 (GLOBE NEWSWIRE) — Streamline Health Solutions, Inc. (NASDAQ: STRM), provider of the eValuator Revenue Integrity Program to help healthcare providers proactively address revenue leakage and financial performance, today announced that it will release its financial results for the three months ended October 31, 2021 on Wednesday, December 8, 2021 after the close of the financial markets.

The Company will conduct a conference call on Thursday, December 9, 2021 at 9:00 AM ET to review results and provide a corporate update. Interested parties can access the call by joining the live webcast: click here to register. You can also join by phone by dialing 877-407-8291.

A replay of the conference call will be available from Thursday December 9, 2021 at 12:00 PM ET to Thursday, December 16, 2021 at 12:00 PM ET by dialing 877-660-6853 or 201-612-7415 with conference ID 13724715. An online replay of the presentation will also be available for six months following the presentation in the Investor Relations section of the Streamline website, www.streamlinehealth.net.

About Streamline Health

Streamline Health Solutions, Inc. (NASDAQ: STRM) is a leader in pre-bill revenue integrity solutions for healthcare providers. Our eValuator Revenue Integrity Program includes integrated solutions, technology-enabled services and analytics that drive compliant revenue and financial performance across the enterprise. We share a common calling and commitment to advance the quality of life and the quality of healthcare – for society, our clients, the communities they serve, and the individual patient. For more information, please visit our website at www.streamlinehealth.net.

Company Contact:

Jacob Goldberger
Director, Investor Relations and FP&A
(303) 887-9625
jacob.goldberger@streamlinehealth.net

Staff

Recent Posts

ProBio Launches GMP AAV Manufacturing Services at Hopewell Facility to Advance Gene Therapy Development and Manufacturing

HOPEWELL, N.J., Aug. 11, 2025 /PRNewswire/ -- ProBio, a leading contract development and manufacturing organization…

41 minutes ago

Amphastar Announces FDA Approval for Iron Sucrose Injection, USP

According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic…

42 minutes ago

Trump May Reclassify Marijuana – MMJ BioPharma To Escape The DEA’s Seven Year Cannabis Trial Roadblock?

Trump said his administration will focus on research to unlock the medical uses of marijuana,…

42 minutes ago

Relief Therapeutics Advances Publication of 2025 Half-Year Report

GENEVA, SWITZERLAND / ACCESS Newswire / August 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY…

4 hours ago

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

SINGAPORE, Aug. 10, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for…

7 hours ago